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ABSTRACT
Ovarian cancer is a leading cause of cancer mortality in women world-wide. 
Considerable progress has been made to characterize the different subtypes of 
ovarian cancer, but specific therapies remain limited and prognosis poor. Cytokine 
signaling via the interleukin-6 receptor (IL-6R) family and related receptors has 
been implicated in a number of cancers, including those with an ovarian origin. The 
leptin receptor (LEPR) is structurally related to these receptors and utilizes similar 
downstream pathways. LEPR has diverse roles in metabolism, appetite and bone 
formation with obesity linked to both elevated levels of leptin and increased cancer 
incidence. This study investigated a potential role for LEPR signaling in ovarian cancer. 
Leptin stimulation led to increased proliferation, survival and migration of LEPR-
expressing ovarian cancer cell lines, with the effects shown to be mediated by the 
downstream Janus kinase 2/Signal transducer and activator of transcription 3 (JAK2/
STAT3) pathway. A significant correlation was identified between high co-expression 
of leptin and LEPR and decreased patient survival. This study collectively suggests 
that leptin/LEPR signaling via JAK2/STAT3 has the potential to significantly impact on 
pathogenesis in a subset of ovarian cancer patients who may benefit from strategies 
that dampen this pathway.
INTRODUCTION
Ovarian cancer remains the most lethal gynecological 
cancer, and represents one of the major causes of cancer 
morbidity and mortality in women worldwide [1]. This 
is partly as a result of the largely asymptomatic nature 
of early disease, with women usually presenting with 
advanced disease when the tumor has already spread into 
the peritoneum and sometimes to distant metastatic sites [2]. 
In addition, there remains only limited knowledge of the 
molecular factors contributing to ovarian cancer etiology 
with which to inform specific therapeutic strategies. 
Despite treatment with aggressive surgery followed by 
chemotherapy, ovarian cancer patients experience <40% 
survival at 5 years, principally due to recurrent disease 
including metastasis [1].
Leptin is a cytokine with a wide variety of biological 
roles including regulation of energy metabolism, appetite, 
bone formation and angiogenesis [3]. High levels of leptin 
are observed in obese individuals [4], and these individuals 
have an increased risk of diabetes, fatty liver disease and 
cancer [5]. Indeed, leptin has been shown to have an 
important role in cell proliferation, invasion, metastasis 
and/or survival in several cancer types, such as breast, 
liver, colon, esophageal and endometrial cancers [6–10], 
including a role in ovarian cancer proliferation [11]. In 
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breast cancer, the effects of leptin have been shown to 
be mediated through the activation of specific genes by 
STAT3, including cyclin D1 and c-Myc for proliferation 
[12] and VEGF and its receptor for angiogenesis [13].
Leptin exerts its action through a specific 
homodimeric receptor called leptin receptor (LEPR) [14]. 
LEPR is structurally related to the common signaling 
chain of the interleukin-6 receptor (IL-6R) family of 
cytokine receptors, glycoprotein 130 (GP130), as well as 
granulocyte colony-stimulating factor receptor (G-CSFR). 
Each of these receptor chains signals via the Janus kinase 
2/Signal transducer and activator of transcription 3 (JAK2/
STAT3) pathway [15]. Importantly, aberrant signaling 
by IL-6R and G-CSFR has been shown to contribute to 
key ovarian cancer phenotypes, including proliferation, 
migration and resistance against apoptosis [16–19].
These factors have led us to investigate the role of 
LEPR signaling in ovarian cancer. Analysis of ovarian 
cancer cell lines expressing functional LEPR revealed 
that leptin induced proliferation of adenocarcinoma cell 
lines and stimulated both survival and migration in both 
adenocarcinoma and teratocarcinoma cell types. These 
effects of leptin were shown to be mediated by the JAK2/
STAT3 pathway. Further analysis revealed that high co-
expression of leptin and LEPR correlated with reduced 
survival in ovarian cancer patients.
RESULTS
Expression of LEPR in ovarian cancer
Correlations between leptin levels and cancer have 
been described previously [5], while leptin signaling via 
LEPR has been implicated in breast and other cancers [8, 
10]. Moreover, structurally-related members of the IL-6R 
family, including IL-6R and G-CSFR, have been shown 
to contribute to ovarian cancer progression [18, 19]. 
Therefore, the potential role of LEPR signaling in ovarian 
cancer biology was investigated. Preliminary experiments 
revealed vastly different levels of LEPR expression 
in a group of Grade 3 ovarian tumors (Supplementary 
Figure 1A) that was confirmed in a panel of 52 cell lines 
representing a range of different ovarian cell sub-types 
(Supplementary Figure 1B) and in 484 ovarian cancer 
samples (Supplementary Figure 2).
Role of LEPR signaling in ovarian cancer cells
To identify suitable cell models to investigate 
the functional significance of LEPR expression, FACS 
analysis was performed on a set of ovarian cancer lines 
in-hand. This identified adenocarcinoma (HEY3, SKOV3) 
and teratocarcinoma (PA1) cell lines expressing LEPR, 
along with adenocarcinoma (A2780) and clear cell 
carcinoma (ES2) cell lines that did not express detectable 
LEPR (Figure 1A). RT-PCR analysis confirmed the 
expression of the ‘long’ LEPR isoform in HEY3, SKOV3 
and PA1 cells (Supplementary Figure 3), and data not 
shown which is the form capable of intracellular signaling 
[14, 20, 21], with leptin treatment able to increase this 
isoform in HEY3 cells only (Supplementary Figure 3).
Cytokines are known to stimulate proliferation, 
survival and migration in responsive cells, and so these 
parameters were assessed in response to leptin stimulation. 
Leptin elicited a significant increase in proliferation in 
LEPR-positive HEY3 and SKOV3 cells, a marginal but 
non-significant response in PA1 cells, and no response 
in the LEPR-negative A2780 and ES2 cells (Figure 1B). 
This response was dose-dependent (Figure 1F) and could 
be inhibited by a specific leptin inhibitor (Figure 1G). 
With respect to survival, the cell lines showed very low 
levels of apoptosis even in low serum, and so apoptosis 
was induced by the addition of sodium azide in order 
to evaluate potential anti-apoptotic responses. Leptin 
provided variable but statistically significant protection 
against apoptosis in the LEPR-positive PA1, HEY3 and 
SKOV3, but not in A2780 and ES2 cells (Figure 1C). 
This effect was confirmed in HEY3 cells treated with the 
clinically-relevant therapeutic agent cisplatin (Figure 1H). 
Cell migration was also examined in these cells using a 
wound-healing assay, and was found to be increased upon 
leptin stimulation in the cell lines expressing LEPR (PA1, 
HEY3 and SKOV3) but not in the LEPR-negative (A2780 
and ES2) cells (Figure 1D, 1E). This effect was similar 
in the presence of the proliferation inhibitor hydroxyurea 
(Figure 1I), indicating it was independent of cell division.
LEPR acts via the JAK2/STAT3 pathway in 
ovarian cancer cells
Leptin is known to activate a number of different 
signaling pathways, particularly the JAK2/STAT3 pathway 
[21], including in cancer cells [6]. To investigate whether 
the LEPR utilizes this pathway in ovarian cancer cells, 
representative cell lines were analyzed for activation of 
STAT3. Leptin stimulation led to a robust increase in 
phosphorylated STAT3 (pSTAT3) that correlated with the 
LEPR expression levels in PA1 and HEY3, but this was not 
observed in LEPR-negative ES2 cells, despite comparable 
levels of total STAT3 and GAPDH used to confirm 
equivalent loading (Figure 2A). To determine whether 
the effects on STAT3 phosphorylation translated to active 
nuclear STAT3, nuclear extracts were analyzed by EMSA 
using a STAT3-binding site. Leptin induced STAT3 binding 
that mirrored pSTAT3 levels, with strong leptin-dependent 
binding in PA1 and HEY3 cells, but not in ES2 cells, despite 
robust STAT3 activation by IL-6 in each cell line (Figure 
2B). The expression of representative STAT3 responsive 
genes following leptin stimulation was examined using 
semi-quantitative RT-PCR: ICAM1, MMP2 and MMP9 for 
migration, MYC and CCND1 for proliferation, and BCL2 
for survival. Leptin treatment increased the expression of 
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Figure 1: Effects of leptin/LEPR stimulation on ovarian cancer cell phenotypes. (A) Expression of LEPR in a panel of 
representative ovarian cancer cell lines. The indicated cells were subjected to FACS analysis using anti-LEPR (red line) or an isotype 
control (black line) to quantify cell surface expression. (B, F-G) Proliferation assay. Cell counts for the indicated cell lines over a period 
of 3 days either untreated (–) or treated with 100 ng/ml leptin (Lep) (B,G) or a range of leptin concentrations (0, 1, 10 and 100 ng/ml) (F) 
alone, or in the presence of leptin inhibitor (inh) (G). The graphs represents the mean and SEM of three independent experiments (*p<0.05). 
(C, H) Apoptosis assay. Apoptosis of the indicated cell lines induced by either sodium azide (C) or cisplatin (H), when untreated (–) or 
treated with 100 ng/ml leptin (Lep). Graphs show the mean percentage and SEM of three independent experiments of apoptotic cells pre- 
and post-leptin treatment (*p<0.05). D-E,I. Migration assay. The indicated cell lines, either untreated (–) or treated with 100 ng/ml leptin 
(Lep) alone (D-E) or in combination with hydroxyurea (I), were subjected to wounding and imaged at 0 h and 15 h. Representative images 
are provided (D), along with graphs showing the mean wound closure and SEM from three independent experiments (E,I) (*p<0.05).
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each of these genes in the LEPR-positive cell lines (PA1 
and HEY), but produced no change in the LEPR-negative 
cell line (ES2), with ACTB used as a control (Figure 
2C). The increases in gene expression were subsequently 
quantified by Real-Time RT-PCR, which confirmed 
statistically significant induction in all but one case (Figure 
2D). Induction of the encoded protein was also verified in 
PA1 cells by zymography for MMP9 (Figure 2E) and by 
Western blot analysis for ICAM1 and BCL2 (Figure 2F). 
Importantly, specific inhibitors for both JAK2 and STAT3 
effectively blocked leptin-induced STAT3 activation (Figure 
2G) and gene induction (data not shown) in PA1 and HEY3 
cell lines, confirming a functional JAK2-STAT3 pathway. 
Similar results were obtained in SKOV3 cells (data not 
shown).
To confirm that signaling via the JAK2-STAT3 
pathway also contributed to the leptin/LEPR-induced 
phenotypes, responsive cell lines were re-analyzed 
for these phenotypes in combination with the specific 
inhibitors for JAK2 and STAT3. Both inhibitors were able 
to suppress leptin-mediated proliferation (Figure 3A), 
survival (Figure 3B) and migration (Figure 3C) in LEPR-
expressing ovarian cancer cells.
High leptin/LEPR coexpression represents a 
poor prognostic factor in ovarian cancer
To assess the clinical consequences of LEP and LEPR 
expression, survival analysis was performed on ovarian 
cancer patients, comparing groups expressing LEP or LEPR 
above and below the median level. This revealed a non-
significant trend for decreased survival in patients with high 
levels of either LEP (hazard ratio 1.20, 95% CI 0.95-1.51) 
(Figure 4A) or LEPR (hazard ratio 1.23, 95% CI 0.97-1.55) 
(Figure 4B). However, a statistically significant decrease in 
survival was identified for patients with high expression of 
both LEP and LEPR (hazard ratio 1.45, 95% CI 1.05-1.99; 
median survival 1204 v. 1448 days) (Figure 4C), despite no 
difference in expression of JAK2 or STAT3 (Supplementary 
Figure 7). This effect was heightened in patients in the top 
tertile for LEP (hazard ratio 1.27, 95% CI 0.96-1.68) (Figure 
4D) or LEPR (hazard ratio 1.24, 95% CI 0.93-1.64) (Figure 
4E) and particularly for both LEP and LEPR compared to 
those in the bottom tertiles (hazard ratio 1.77, 95% CI 1.07-
2.92; median survival 1199 v. 1746 days) (Figure 4F).
DISCUSSION
Leptin signaling via LEPR has a wide variety of 
roles in regulating energy metabolism, appetite regulation, 
bone formation and angiogenesis [3, 22, 23]. LEPR 
achieves this by initiating downstream signal cascades, 
including the JAK2/STAT3 pathway. Several studies have 
indicated that LEPR signaling can induce cancer cell 
adhesion, angiogenesis, proliferation, survival, migration 
and stem cell-ness in several malignancies [8, 10, 24-27]. 
However, whether LEPR-mediated signaling impacted on 
ovarian cancer remained poorly understood.
This study identified leptin-induced migration 
of LEPR-positive ovarian cancer cells mediated via 
JAK2/STAT3. Previous studies have shown that leptin 
can induce cancer cell migration via the MAP kinase in 
prostate cancer [26], via the AKT pathway in endothelial 
cells [28], via the NF-kB pathway in glioma cells [29], 
and via the JAK/STAT, PI3K/AKT, and MAPK pathways 
in hepatocellular carcinoma cells [8]. This indicates that 
leptin can utilize multiple pathways to influence cancer 
cell migration, although we showed that in ovarian 
cancer cells inhibition of the JAK2/STAT3 pathway was 
sufficient to block this effect. A role for leptin/LEPR in 
the survival of ovarian cancer cells was also demonstrated, 
similarly through the JAK2/STAT3 pathway, consistent 
with a previous study showing an alternate JAK2 inhibitor 
was able to induce apoptosis in ovarian cancer cells [30].
Our data has also shown that leptin/LEPR signaling 
enhanced proliferation in the HEY3 and SKOV3 
adenocarcinoma cell lines also via JAK2/STAT3. Two 
previous studies have demonstrated leptin-mediated 
proliferation of ovarian cancer cells via the MAPK 
pathway and PI3K pathways [11, 31]. Importantly, both 
pathways typically lies downstream of JAK2 and so 
are likely blocked with the JAK2 inhibitors used in this 
study. However, since leptin-induced proliferation was 
also abrogated with the STAT3 inhibitor, it appears that 
STAT3-mediated pathways contribute to proliferation 
independently of MAPK or PI3K. Leptin has also been 
reported to activate the estrogen receptor pathway 
[32], providing an alternative mechanism to impact on 
proliferation. Collectively, this work has shown that 
LEPR signaling is able to positively impact on several 
key tumor-promoting phenotypes that are also influenced 
by other IL-6R-related receptors, such as IL-6R itself [19] 
and G-CSFR [18].
Amongst the LEPR-positive cell lines proliferation, 
migration and survival responses did not correlate well 
with relative LEPR expression, although this did correlate 
with the extent of leptin-mediated STAT3 activation. 
This is complicated by the fact that leptin induced LEPR 
expression in HEY3 cells (Supplementary Figure 3). 
Moreover, use of a LEPR-Fc ‘decoy’ abrogated leptin 
responses ruling out the possibility that some effects 
were LEPR-independent. Importantly, expression of key 
STAT3-target genes (eg. MYC) correlated well with the 
relevant phenotypes observed.
Obesity is considered an important etiological 
factor for cancer that is associated with increased 
incidence of many common types of cancers [33]. 
Elevated levels of leptin are observed in obese 
individuals [4], with several studies reporting a 
correlation between obese individuals, high leptin levels 
and enhanced risk of breast, prostate and endometrial 
cancers [26, 34–36]. We identified that high tumor 
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Figure 2: Activation of the JAK2/STAT3 pathway by leptin/LEPR in ovarian cancer. (A) Activation of STAT3 by leptin. 
Cell lysates from the indicated cell lines, either untreated (–) or treated for 45 min with 100 ng/ml leptin (Lep), were analyzed for STAT3 
activation by Western blot with anti-phospho-STAT3, along with anti-STAT3 and anti-GAPDH to confirm equivalent loading. Experiments 
were performed thrice and blots are representative from one experiment (Supplementary Figure 4). (B) Induction of STAT3 DNA 
binding activity by leptin. Nuclear extracts from the indicated cell lines, either untreated (–) or treated for 45 min with 100 ng/ml leptin 
(Lep), interleukin-6 (IL-6), or leptin and leptin-inhibitor (inh) and analyzed for STAT3 activation by EMSA with a STAT3 (m63) probe. 
Experiments were performed thrice and blots are representative of one experiment. (C-D) Expression of STAT3 responsive genes by leptin. 
Cells, either untreated (–) or treated with 100 ng/ml leptin (Lep), were analyzed by semi-quantitative RT-PCR (C), with the fold change 
and SEM quantified by subsequent Real-Time RT-PCR (D) (*p<0.05). (E-F) Induction of STAT3 target gene products by leptin. PA1 cells, 
either untreated (–) or treated with 100 ng/ml leptin (Lep), were analyzed by gelatin zymography for MMP9 (E) and Western blot analysis 
for ICAM-1, BCL2 and GAPDH (F). (G) Leptin-induced STAT3 activation is blocked by specific inhibitors of the JAK2/STAT3 pathway. 
Lysates were prepared from cells, either untreated (–) or treated with 100 ng/ml leptin (Lep), without inhibitors (con) or with specific 
inhibitors for STAT3 (S3I) or JAK2 (J2I), as indicated, and analyzed for STAT3 phosphorylation as per panel A (Supplementary Figure 5).
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expression of LEP and LEPR separately showed a 
trend toward poor survival. This was supported by 
another study for LEP [37] and our own analysis of 
an alternate data set [38] for LEPR that emphasised a 
role in long-term survival (hazard ratio 1.18, CR 1.03-
1.34) (Supplementary Figure 6). Furthermore, high co-
Figure 3: Effects of Leptin/LEPR on cell proliferation, survival and migration are mediated via the JAK2/STAT3 
pathway. (A) Proliferation assay. Cell counts over a period of 3 days for the cells indicated either untreated (–) or treated with 100 ng/ml 
leptin (Lep), with or without specific inhibitors for STAT3 (S3I) or JAK2 (J2I), as indicated. The graph represents the mean and SEM of 
three independent experiments (*p<0.05). (B) Apoptosis assay. Percentage of apoptosis for the indicated cell lines when treated with sodium 
azide alone, or with leptin (Lep) treatment, in the presence or absence of inhibitors for STAT3 (S3I) and JAK2 (J2I). The graph shows mean 
and SEM (n=3; *p<0.05 compared to untreated; **p<0.05 compared to leptin treated). (C) Migration assay. Percentage of wound closure for 
the indicated cell lines, either untreated (–) or treated with 100 ng/ml leptin (Lep), in the presence or absence of inhibitors for STAT3 (S3I) 
or JAK2 (J2I), as indicated, showing mean and SEM (*p<0.05).
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expression of LEP and LEPR within the tumor clearly 
represented a poor prognostic factor for epithelial 
ovarian cancer, consistent with another recent study 
[39]. However, the major source of leptin production 
is subcutaneous fat [40]. Thus, individuals with LEPR-
positive cancers could be particularly susceptible to 
high leptin levels seen in obesity irrespective of LEP 
expression in the tumor itself. High BMI has been 
associated with increased risk of ovarian cancer [41, 
42], although not in high-grade serous cancers [41]. 
However, amongst women with ovarian carcinoma, 
increased BMI was associated with reduced disease-
specific survival [43–45], including in high-grade serous 
cancer [45]. Importantly, amongst women with epithelial 
ovarian cancer, there was a significant correlation 
between BMI and leptin levels, with patients with a low 
leptin:adiponectin ratio demonstrating statistically longer 
disease-specific survival [46]. This suggests weight 
control could potentially contribute to positive outcomes 
in ovarian cancer, and particularly those patients with 
LEPR-positive tumors. Additional therapeutic options 
should also be considered for these patients, such as 
JAK/STAT inhibitors, which are already being used in 
various clinical settings [47].
This paper has demonstrated that ovarian cancer 
cells expressing LEPR can signal through the JAK2/STAT3 
pathway to contribute to key cancer phenotypes. This 
was consistent with high co-expression of LEP and LEPR 
correlating with poor survival of ovarian cancer patients. This 
suggests that further research into weight control strategies and 
JAK/STAT inhibitors in this clinical setting are warranted.
Figure 4: Impact of leptin/LEPR expression on ovarian cancer patient survival. Overall survival curves of ovarian cancer 
patients expressing high (above median, red) versus low (below median, black) levels of LEP (A), LEPR (B) or both LEP and LEPR (C), 
or those expressing higher (top tertile, orange) versus lower (bottom tertile, purple) levels of LEP (D), LEPR (E) or both LEP and LEPR 
(F) (*p<0.05).
Table 1: Clinical characteristics of patients in the 
TCGA ovarian cancer cohort
Clinical parameter Details
Total patient cohort 559
Age at time of pathology 
(n=549)
 - Mean: 59.7 ± 11.6 years
 - Range: 26-89 years
Cancer stage (n=546)
 - I: 13 (IA=1, 1B=3, IC=9)
 - II: 27 (IIA=3, IIB=4, IIC=20)
 - III: 424 (IIIA=7, IIIB=23, IIIC=394)
 - IV: 82
Radiation therapy 
(n=559)
 - yes 32
Chemotherapy (n=541)
 - yes 529
  - Carboplatin 486
  - Paclitaxel 485
  - Cisplatin 156
  - Doxorubicin 154
  - Gemcitabine 144
  - Topotecan 122
  - Doxetaxel 117
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MATERIALS AND METHODS
Cell lines and clinical samples
The human epithelial ovarian cancer line HEY3 was 
obtained from the Royal Women’s Hospital Melbourne, 
A2780 from Deakin University, while PA1, SKOV3, 
and ES2 were obtained from American Type Culture 
Collection (Rockville, MD). Cell lines were grown as 
monolayers in 25 or 75 cm2 flasks (BD, Australia) in 
complete growth medium consisting of Basal Medium 
Eagle for PAI, McCoy’s 5a for SKOV3 and ES2, 
Dulbecco’s Modified Eagle’s Medium (DMEM) HEY3, 
and RPMI1640 for A2780, in each case supplemented with 
10% (v/v) heat-inactivated fetal bovine serum and 2 mM 
glutamine (Invitrogen Corporation, Melbourne, Australia) 
in the presence of 37°C with 5% CO2. Recombinant human 
leptin (Sigma Aldrich, Melbourne, Australia) was used at 
0-100 ng/ml, along with recombinant mouse LEPR-Fc 
chimera (Leptin inhibitor, 0.5 μg/ml) (R&D Systems, 
Minneapolis, MN, USA), WP1066 (JAK2 inhibitor, 2.5 
μM) and LLL12 (STAT3 inhibitor, 2.5 μM) (BioVision, 
Mountain View, CA, USA), cisplatin (20 μg/ml) 
(Pfizer, Perth, WA, Australia), sodium azide (0.5%) and 
hydroxyurea (50 μM) (Sigma Aldrich), as required. 
Grade 3 serous ovarian carcinomas were collected from 
patients after obtaining written informed consent under 
protocols approved via the Victorian Cancer Biobank 
and approved by the Deakin University Human Research 
Ethics Committee (DUHREC#2010-104). All patients had 
undergone chemotherapy with standard agents.
Receptor expression analysis
Confluent cell lines were harvested for fluorescence 
activated cell sorter (FACS) analysis. Cell monolayers 
were washed twice with phosphate buffered saline (PBS), 
detached with 0.25% (w/v) trypsin-EDTA solution, 
collected by centrifugation and washed a further two times 
with PBS. Approximately 1×106 cells were fixed using 4% 
(w/v) paraformaldehyde (PFA) and subsequently blocked 
for 30 min in PBS containing 10% (v/v) goat serum. 
After incubation, the cells were washed twice with PBS, 
incubated with 1 μg/μl anti-LEPR antibody or isotype 
control (AbCam, USA) at room temperature, then washed 
three times in PBS before incubation with goat anti-rabbit 
Alex Fluro® 488 (Invitrogen) at 1/500 dilution for 60 min 
at room temperature. Samples were analysed on a FACS 
Canto (BD Bioscience) using FACS DIVA and FlowJo 
software, in comparison to appropriate controls.
Growth assay
Growth rates were assessed as previously described 
[19]. Briefly, 1×105 cells were seeded onto a six well 
plate in appropriate media. Each day the cells were 
trypsinized, resuspended in medium and counted using 
a hemocytometer. Each experiment was performed in 
triplicate for each harvest and repeated thrice.
Apoptosis assay
Apoptosis was quantified by double-staining with 
Annexin V-FITC and propidium iodide (PI) using an 
Apoptosis Detection Kit (BD Biosciences), as we have 
described previously [48].
Cell migration assay
The migratory potential of ovarian cancer cells was 
assessed using a wound healing assay, as previously described 
[19]. Briefly, cells were grown to a confluent monolayer in 
a 6-well plate and ‘wounded’ with a sterile 200 μl pipette 
tip. Three representative fields were marked and imaged at 0 
h and 15 h. Images were captured using an Olympus SC20 
camera, with the width of the scratches was measured at each 
time point and quantified using Cell Profilier®.
Western blot analysis
Proteins were extracted using RIPA Lysis buffer 
containing Phosphatase Inhibitor Cocktail (Sigma Aldrich, 
Sydney, Australia) according to the manufacturer’s 
instructions. Protein concentration was quantified using 
a BCA Protein Determination Kit (Pierce) as per the 
manufacturer’s instructions and absorbance read at 
562 nm on a PerkinElmer VICTOR X Multilabel Plate 
Reader. Western blots were performed as previously 
described [19], utilizing rabbit antibodies against phospho-
STAT3 (Tyr 705), total-STAT3, BCL2 and ICAM-1 (Cell 
Signaling, Beverly, MA, USA), and a mouse monoclonal 
antibody against GAPDH (Millipore Technologies, 
Sydney, Australia) at 1:1000 dilution, followed by anti-
rabbit IRDyeTM 680 CW and anti-mouse IRDyeTM 800 
CW (LI-COR Biosciences, Nebraska, USA) at 1:10000 
dilution in 5% (w/v) BSA in TBS containing 0.1% Tween. 
Images were obtained using an Odyssey Imaging System 
(LI-COR Biosciences) and analysed with ImageJ (NIH).
Gelatin zymography
Conditioned media from cells cultured for 12-24 h 
was mixed with sample buffer and subjected to SDS-PAGE 
using gels containing 10% (w/v) gelatin. These were 
soaked three times for 30 min at room temperature in PBS 
containing 2.5% Triton X-100, before incubation for 24 h 
at 37°C and then staining with 0.1% Coomassie Brilliant 
Blue R-250.
EMSA
Nuclear extracts were prepared and analysed by 
electrophoretic mobility shift assay (EMSA) using the 
m67 high affinity STAT binding site probe, as described 
previously [48].
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Reverse transcription-polymerase chain reaction
RNA extraction and reverse transcription-
polymerase chain reaction (RT-PCR) were performed as 
described [19] using the following primer pairs: LEPR long 
form 5’-TTGTGCCAGTAATTATTTCCTCTT and 5’-ATA 
GCTTTTTCATTCTTTGGTGTG, LEPR short form 1 
reverse 5’-CTGTGGCCTTCCGCAGTG, LEPR short form 
2 reverse 5’-ACCTCCACCCAGTAGTTCCTT, LEPR 
short form 3 reverse 5’-AGTTGGCACATTGGGTTCAT, 
LEP 5’-GAAGACCACATCCACACACG and 5’-AG 
CTCAGCCAGACCCATCTA, LEP 5’-GAAGACCACA 
TCCACACACG and 5’-AGCTCAGCCAGACCCATCTA, 
ICAM1 5’-GGCTGGAGCTGTTTGAGAAC and 5’-AC 
TGTGGGGTTCAACCTCTG, CCND1 5’-CCTAAGTTC 
GGTTCCGATGA and 5’-ACGTCAGCCTCCACACT 
CTT, BCL2 5’-GGATGCCTTTGTGGAACTGT and 5’-A 
GCCTGCAGCTTTGTTTCAT, MMP2 5’-ATGACAGC 
TGCACCACTGAG and 5’-ATTTGTTGCCCAGGAAA 
GTG, MMP9 5’-TTGACAGCGACAAGAAGTGG and 
5’-GCCATTCACGTCGTCCTTAT, MYC 5’-TACCCTC 
TAACGACAGCAG and 5’-TCTTGACATTCTCCTC 
GGTG, and ACTB 5’-GGACTTCGAGCAAGAGATGG 
and 5’-AGCACTGTGTTGGCGTACAG. PCR products 
were visualized on 1-3% (w/v) agarose gels containing 
SYBR® Safe (Invitrogen) and imaged using a Chemidoc 
XRS Molecular Imager System (Bio-Rad). Gene 
expression was measured by quantitative RT-PCR (qRT-
PCR) on an Agilent Stratagene MX3000P. Reactions 
(25 μL) contained 3.125 μL nuclease-free water, 3.125 μL 
cDNA template (1:10 dilution), 12.5 μL iQ SYBR Green 
Supermix (Bio-Rad) and 3.125 μL each of forward and 
reverse primer (2.4 μM). Typical PCR conditions consisted 
of 95°C for 30 sec, followed by 45 cycles of 95°C for 10 
sec, 60°C for 30 sec, 72°C for 20 sec, then 95°C for 1 min, 
58°C for 1 min, and finally incremental increases (0.5°C) 
from 58°C to 95°C to establish the melting curve for each 
sample. Appropriate control reactions were performed to 
ensure products were not the result of DNA contamination 
or due to primer-dimer formation. Data retrieved from 
these assays were analysed using the Livak method [49].
Bioinformatic analysis
Expression data for 52 ovarian cancer cell lines of 
diverse subtypes were extracted from the Cancer Cell Line 
Encyclopedia (CCLE) (http://www.broadinstitute.org/ccle/
home), which uses the Affymetrix U133+2 array platform 
(downloaded 18 Sep 2014). Expression data for 586 primary 
serous adenocarcinomas of the ovary and 8 normal ovary 
samples were obtained from The Cancer Genome Atlas 
(TCGA) (http://cancergenome.nih.gov), which uses the 
Affymetrix U133A array platform, along with clinical details 
for the 559 ovarian cancer patients with available survival 
data (Table 1) (downloaded 6 Mar 2014). Expression data 
were converted to a single value for each probe set using 
Robust Multi-array Average (RMA) approach with quartile 
normalization [50]. Survival curves were generated from 
this database, as well as one of approximately 1300 ovarian 
cancer patients with predominantly serous carcinoma 
(accessed 30 Nov 2015) [38], with comparisons based on 
relative LEP and LEPR expression using the Kaplan Meier 
method and log-rank hazard model.
Statistical analysis
The cell phenotype parameters investigated follow 
a normal distribution and were analysed by a 2-sample 
Student’s t test for pairwise comparisons of independent 
samples and One-way analysis of variance (ANOVA) for 
multiple comparisons using GraphPad Prism and SPSS 
software packages. Patient survival data was analyzed 
with Mantel-Cox methodology in GraphPad Prism. In 
each case, p<0.05 was considered statistically significant.
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